strategic alternatives
Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends
Kezar Life Sciences; FDA setback; strategic alternatives; zetomipzomib; autoimmune hepatitis; Taysha Gene Therapies; Astellas; Rett syndrome; TSHA-102; clinical trials
Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul
Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development
Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options
Leap Therapeutics; workforce reduction; biotech layoffs; clinical trial; strategic alternatives; sirexatamab; FL-501; R&D wind down
Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives
Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%
Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide
Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology
Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth
Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments
Lava cuts jobs by 30% after key drug discontinued
LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway
Viracta Therapeutics Shuts Down Operations, Lays Off Entire Workforce
biotech closure, oncology company, financial troubles, workforce termination, wind-down operations, Nasdaq delisting, strategic alternatives
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges
Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review
Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A